Federal Register / Vol. 89, No. 224 / Wednesday, November 20, 2024 / Notices 91775 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; Clinical Trial Readiness 

Review Meeting. 

Date: December 13, 2024. 

Time: 10:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852. 

Meeting Format: Virtual Meeting. 

Contact Person: Ana Olariu, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Activities, 

NINDS/NIH/DHHS, NSC, 6001 Executive 

Boulevard, Rockville, MD 20852, 301–496– 

9223 Ana.Olariu@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS). 

Dated: November 14, 2024. 

David W. Freeman, 

Supervisory Program Analyst, Office of 

Federal Advisory Committee Policy. 

[FR Doc. 2024–27047 Filed 11–19–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

Periodically, the Substance Abuse and 

Mental Health Services Administration 

(SAMHSA) will publish a summary of 

information collection requests under 

OMB review, in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

Chapter 35). To request a copy of these 

documents, call the SAMHSA Reports 

Clearance Officer on (240) 276–0361. 

Project: Zero Suicide in Health Systems 

Evaluation—New Package 

The Substance Abuse and Mental 

Health Services Administration 

(SAMHSA)’s Center for Mental Health 

Services (CMHS) is requesting clearance 

for the new data collection associated 

with the evaluation of the SAMHSA 

Zero Suicide in Health Systems (Zero 

Suicide Evaluation). The Zero Suicide 

program is authorized under the CURES 

Act. SAMHSA is required to evaluate 

the Zero Suicide grant, specifically (1) 

evaluate the activities supported by 

grants awarded, disseminate, as 

appropriate, the findings from the 

evaluation; and (2) provide appropriate 

information, training, and technical 

assistance, as appropriate, to eligible 

entities that receive a grant under this 

section, in order to help such entities to 

meet the requirements of this section, 

including assistance with selection and 

implementation of evidence. 

The goal of the Zero Suicide program 

is the reduction of suicide and suicide 

attempts across America, focusing on 

individuals who are 25 years and older. 

The purpose of this program is to 

implement the Zero Suicide 

intervention and prevention model for 

adults throughout a health system or 

systems. The Zero Suicide model is a 

comprehensive, multi-setting approach 

to suicide prevention in health systems. 

To accomplish this critical, lifesaving 

work, it is essential that the 

effectiveness of these programs be 

evaluated on an ongoing basis, with 

implementation of suicide prevention 

programs continually informed by highquality evaluation results. SAMHSA 

will use this data to reduce suicide 

ideation, suicide attempts, and deaths 

due to suicide. 

SAMHSA has awarded new grants 

and continued funding to 25 grantees, 

Cohort 5 (15 grantees) with project 

period of Sept 30, 2023, to Sept 29, 

2028; and Cohort 4 (10 grantees; 

includes one tribal organization) with 

project period of March 31, 2021, to 

March 30, 2026. SAMHSA has 

requested funding for 11 grantees to be 

funded as Cohort 6 in the fiscal year 

2025. 

The Zero Suicide Evaluation is 

designed to evaluate the 

implementation, effectiveness, and 

overall impact of the Zero Suicide 

program upon grantees in the United 

States. The evaluation will assess Zero 

Suicide program activities implemented 

by grantees and ultimately provide 

SAMHSA with the information needed 

to understand and document program 

effectiveness on reducing suicide 

morbidity and mortality, specifically 

among those who encounter the 

healthcare system. While 

acknowledging the lack of evidence for 

cultural adaptations to evidence-based 

and empirically supported treatments 

and interventions, and that research has 

not been conducted with historically 

marginalized and underserved 

communities (e.g., Black, Asian, 

Autistic, Lesbian, Gay, Bisexual, 

Transgender, Queer, Intersex, and 

Asexual Plus (LGBTQIA+), and others), 

Zero Suicide pushes systems to ensure 

that clients’ cultural contexts are 

considered and honored in what 

treatments are offered and how those 

treatments are adapted. Thus, with 

behavioral health equity as a central 

component woven throughout the Zero 

Suicide Framework, the proposed 

evaluation will ensure that each study 

includes specific behavioral health 

equity tenets to ensure a culturally 

specific understanding of Zero Suicide 

implementation, outcomes, and 

impacts. 

The Zero Suicide Evaluation includes 

four studies: Systems Change, Work 

Force, Consumer Experience, and 

Impact. The purpose of the Systems 

Change Study is to understand how 

grantees are implementing the Zero 

Suicide Program. The Systems Change 

Study collection instruments include 

the: Prevention Strategies Inventory 

(PSI), Behavioral Health Provider 

Survey (BHPS), Case Studies, and Cost 

Sub-Studies. 

The purpose of the Workforce Study 

is to document staff awareness and 

perceptions associated with the Zero 

Suicide activities implemented by Zero 

Suicide-participating Healthcare 

Organizations (HCOs). The Workforce 

Study instruments include the: Work 

Force Survey (WFS), Training Activity 

Summary Page (TASP), and the Training 

Utilization and Preservation Survey 

(TUPS). 

The purpose of Consumer Experience 

Study is to understand the relationship 

between Zero Suicide activities and key 

clinical outcomes (i.e., suicide risk, 

depression), along with consumer 

perceptions of care, access to care, 

services received, and treatment 

adherence. The Consumer Experience 

Study instruments include the: BHPS, 

Consumer Experience Survey (CES), 

Clinical Outcomes Form (COF), and 

Grantee Performance Data. 

The Impact Study will use secondary 

data and quasi-experimental designs to 

develop a control group and estimate 

the causal impact of the Zero Suicide 

Program on suicide morbidity and 

mortality. 

Ultimately, the purpose of the Zero 

Suicide Evaluation is to build the 

program’s knowledge base of 

effectiveness by thoroughly describing 

the implementation, outcomes, and 

impact of a program meant to reduce 

deaths by suicide. 

The total annualized burden is an 

estimated 15,504 respondents for the 

Zero Suicide instruments, with a 

combined hourly estimate to be 4,902 

hours. Burden estimates are based on 

the data collection requirements and the 

number of respondents. The estimated 

response burden to collect this 

information associated with the Zero 

Suicide Evaluation annualized over the 

requested 3-year clearance period is 

presented below: 


khammond on DSK9W7S144PROD with NOTICES
91776 Federal Register / Vol. 89, No. 224 / Wednesday, November 20, 2024 / Notices 

TOTAL AND ANNUALIZED AVERAGES: RESPONDENTS, RESPONSES AND HOURS

Type of respondent Form 

Number of 

respondents 

per year 

Responses 

per 

respondent 

Total 

number of 

responses 

Burden per 

response 

(hours) 

Annual 

burden 

(hours) 

Hourly 

wage 

rate 

Total 

cost 

Project Evaluator 1 ................................. PSI ............................................ 40 4 160 1 160 $61.53 $9,845 

Grantee/HCO administrator 2 ................. BHPS ........................................ 47 1 47 0.5 24 61.53 1,477 

Grantee/HCO administrator 2 ................. KII—Case Studies .................... 7 1 7 1 7 61.53 431 

HCO Staff 3 ............................................ KII—Case Studies .................... 27 1 27 1 27 26.81 724 

Grantee/HCO administrator 2 ................. KII—Cost Sub studies .............. 2 1 2 1 2 61.53 123 

HCO Staff 3 ............................................ WFS .......................................... 9,400 1 9,400 0.25 2,350 26.81 63,004 

Project Evaluator 1 ................................. TASP ......................................... 40 10 400 0.25 100 36.67 3,667 

HCO Staff 3 ............................................ TUPS—Baseline ....................... 3,334 1 3,334 0.25 834 26.81 22,360 

HCO Staff 3 ............................................ TUPS—6 month ........................ 252 1 252 0.5 126 26.81 3,378 

HCO Staff 3 ............................................ TUPS—12 month ...................... 189 1 189 0.5 95 26.81 2,547 

Clinicians ................................................ C—SIF ...................................... 180 8.3 1,494 0.25 374 57.21 21,397 

Consumer .............................................. CES—Baseline ......................... 1,128 1 1,128 0.4 451 7.25 3,270 

Consumer .............................................. CES—6-month .......................... 843 1 843 0.4 337 7.25 2,443 

Consumer .............................................. C—KII ....................................... 15 1 15 1 15 7.25 109 

Total ................................................ ................................................... 15,504 .................... 17,298 .................... 4,902 .............. 134,773 

Abbreviation: HCO = Healthcare Organization. 

1BLS OES May 2022 National Industry-Specific Occupation Employment and Wage Estimates average annual salary for Survey Researchers (code 19–3022); 

https://www.bls.gov/oes/cuSeetrrent/naics5_541720.htm. 2BLS OES May 2022 National Industry-Specific Occupation Employment and Wage Estimates average annual salary for Medical and Health Services Managers 

(code 11–9111); https://www.bls.gov/oes/current/oes119111.htm. 3BLS OES May 2022 National Industry-Specific Occupation Employment and Wage Estimates average annual salary for Community and Social Service Occupations (code 29–1000); https://www.bls.gov/oes/current/oes210000.htm. 4BLS OES May 2022 National Industry-Specific Occupation Employment and Wage Estimates average annual salary for Health Diagnosing and Treating Practitioners (code 29–1000); https://www.bls.gov/oes/current/oes_nat.htm#29-0000. 5BLS OES May 2022 Characteristics of minimum wage workers, 2022; https://www.bls.gov/opub/reports/minimum-wage/2022/home.htm#:∼:text=In%202022%

2C%2078.7%20million%20workers,wage%20of%20%247.25%20per%20hour. 

Written comments and 

recommendations for the proposed 

information collection should be sent 

within 30 days of publication of this 

notice to www.reginfo.gov/public/do/ 

PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. 

Alicia Broadus, 

Public Health Advisor. 

[FR Doc. 2024–27065 Filed 11–19–24; 8:45 am] 

BILLING CODE 4162–20–P 

DEPARTMENT OF THE INTERIOR 

Bureau of Land Management 

[BLM_NV_FRN_MO#4500183119] 

Notice of Segregation of Public Land 

for the Esmeralda Solar Projects, 

Esmeralda County, Nevada 

AGENCY: Bureau of Land Management, 

Interior. 

ACTION: Notice of segregation. 

SUMMARY: Through this notice the 

Bureau of Land Management (BLM) is 

segregating public lands included in 

seven rights-of-way applications, 

serialized as NVNV106386133, for the 

Leeward Esmeralda (NVNV105848463), 

Connect Gen Smoky Valley 

(NVNV105848465), Arevia Gold Dust 

(NVNV105851657), Invenergy Nivloc 

(NVNV105851658), NextEra Esmeralda 

(NVNV105851682), Red Ridge 1 

(NVNV105852204) and Red Ridge 2 

(NVNV105852205) solar energy projects, 

from appropriation under the public 

land laws, including the Mining Law, 

but not the Mineral Leasing or Material 

Sales Acts, for a period of up to 2 years 

from the date of publication of this 

notice, subject to valid existing rights. 

This segregation is to allow for the 

orderly administration of the public 

lands to facilitate consideration of 

development of renewable energy 

resources. The public lands segregated 

by this notice total 117,384.38 acres. 

DATES: This segregation for the lands 

identified in this notice is effective on 

November 20, 2024. 

FOR FURTHER INFORMATION CONTACT: 

Perry B. Wickham, Field Manager, at 

telephone: (775) 482–7801; address: 

P.O. Box 911, 1553 S Main Street, 

Tonopah, NV 89049; or email: 

pwickham@blm.gov. Individuals in the 

United States who are deaf, deafblind, 

hard of hearing, or have a speech 

disability may dial 711 (TYY, TDD, or 

TeleBraille) to access 

telecommunication relay services. 

Individuals outside the United States 

should use the relay services offered 

within their country to make 

international calls to the point-ofcontact in the United States. 

SUPPLEMENTARY INFORMATION: 

Regulations found at 43 CFR 2091.3– 

1(e) and 2804.25(f) allow the BLM to 

segregate public lands within a right-ofway application area for solar energy 

development from the operation of the 

public land laws, including the Mining 

Law, by publication of a Federal 

Register notice. The BLM uses this 

segregation authority to preserve its 

ability to approve, approve with 

modifications, or deny proposed rightsof-way, and to facilitate the orderly 

administration of the public lands. This 

segregation is subject to valid existing 

rights, including existing valid mining 

claims located before this segregation 

notice. Licenses, permits, cooperative 

agreements, or discretionary land use 

authorizations of a temporary nature 

that would not impact lands identified 

in this notice may be allowed with the 

approval of an authorized officer of the 

BLM during the segregation period. The 

lands segregated under this notice are 

legally described as follows: 

Mount Diablo Meridian, Nevada 

T. 1 N., R. 37 E., 

Secs. 1 thru 5 and secs. 8 thru 16, 

unsurveyed; 

Sec. 21, unsurveyed; 

Sec. 22, partly unsurveyed, excepting M.S. 

No. 4895, Placer mining claims Blanco, 

Blanco #1, Blanco #2, Blanco #4, Blanco 

# 5, and Blanco #6; 

Secs. 23 thru 26, unsurveyed; 

Sec. 27, partly unsurveyed, excepting M.S. 

No. 4895, Placer mining claims Blanco, 

Blanco #1, Blanco #2, Blanco #4, Blanco 

# 5, and Blanco #6; 

Secs. 35 and 36, unsurveyed. 

T. 2 N., R. 37 E., 

Secs. 23 thru 26; 

Sec. 32, S1⁄2NE1⁄4, W1⁄2, and SE1⁄4; sec. 33, 

W1⁄2 and SE1⁄4; 

Secs. 34 thru 36. 

Tps. 1 and 2 N., R. 38 E., unsurveyed. 

T.1 N., R. 38 1⁄2 E., 

Secs. 4 thru 9, unsurveyed; 


khammond on DSK9W7S144PROD with NOTICES